Morningstar: Buy these 10 cheap, defensive stocks to survive a rough second quarter and position for better times ahead
But Dave Sekera also says patient investors can position themselves for future success.The stock market has presented investors with an interesting dilemma in the second quarter of 2023: equities are cheap, but market conditions mean it's a difficult time to get bullish.
Sekera doesn't expect much growth for the next couple of quarters, and with a weak start to 2024 he is only projecting a 1.4.% increase in US GDP in 2024. Still, he wrote that this is an opportune moment to position for the next recovery. He explained that interest rates and inflation will come down over the next few years and growth will improve, all of which sets a solid foundation for stocks. For now, Sekera wrote, stocks are likely to stay inside their recent trading range, with positive and negative economic news dictating their course. It might not be exciting, but there will be opportunities to build future positions.
At a sector level, Sekera says small caps are trading 33% below Morningstar's estimate of their fair value, while communications stocks are still at a 30% discount in spite of a recent rally, and real estate trades at a 22% discount.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight Watchers parent’s stock soars after deal to buy weight-management drugs prescriber Sequence closesShares of WW International Inc. which was formerly known as Weight Watchers, soared 25.2% toward a five-week high in premarket trading Tuesday, after the...
Read more »
Investors who think recession fears are overblown should buy this lending stock, JPMorgan saysJPMorgan said the stock is a way to express that 'the recession for which investors have been bracing for well over a year, will be milder than feared.'
Read more »
Weight Watchers parent’s stock soars after deal to buy weight-loss drug prescriber Sequence closesThis deal seems to be tipping the scales in Weight Watchers’ favor, as the parent stock was soaring Tuesday morning off a deal to acquire Sequence, a weight-loss drug prescriber.
Read more »
Goldman: Buy WeightWatchers stock on deal to offer weight-loss drugsGoldman Sachs says WeightWatchers' latest deal could revive the company and help it bring in $1.4 billion by 2025
Read more »
Bankman-Fried reportedly joked about losing track of assets worth millionsInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Vote now: Would you buy the OnePlus Pad?We all know what's up with the smartphone duopoly in the US. It's either Apple or Samsung, pretty much, but now we have a new player on the tablet scene. Would you buy the OnePlus Pad and break the status quo?
Read more »